Fragile X Syndrome clinical trials at University of California Health

6 in progress, 0 open to eligible people

Showing trials for

  • BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome

    Sorry, in progress, not accepting new patients

    This is a 2-part study, with each part having a unique set of objectives for male adolescents aged 9 to < 18 years with fragile X syndrome (FXS). Part 1 is an open-label, single-dose, pharmacokinetics (PK) assessment of BPN14770 25 mg and 50 mg,…

    at UC Davis

  • BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

    Sorry, in progress, not accepting new patients

    A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome

    at UC Davis

  • BPN14770 in Subjects With Fragile X Syndrome

    Sorry, accepting new patients by invitation only

    This is a 4-year, open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301 (in adult males) and Study BPN14770-CNS-204 (in adolescent males).

    at UC Davis

  • Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

    “Children and teens between 3 and 17 diagnosed with Fragile X syndrome may qualify for a clinical trial”

    Sorry, in progress, not accepting new patients

    This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X Syndrome (FXS). …

    at UC Davis

  • Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

    Sorry, accepting new patients by invitation only

    ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel that can be applied to the skin (called transdermal delivery). The gel will be applied to clean, dry, intact skin of the shoulders and/or upper arms. Participants …

    at UC Davis

  • Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities

    Sorry, accepting new patients by invitation only

    This study is a randomized, double-blind, placebo-controlled, crossover trial of extended-release liquid methylphenidate (XRMPH) to evaluate the sensitivity of the NIH Toolbox Cognition Battery (NIHTB-CB) to changes in cognition in children and…

    at UC Davis

Our lead scientists for Fragile X Syndrome research studies include .

Last updated: